Skip to main content
OpenTrials
Completed

NCT Number: NCT02963636

Proximity Work in Family Medicine Groups : the Impact of Pharmacists

The project objective is to evaluate the impact of the recent addition of pharmacists within family medicine groups (FMGs) on organizational and clinical parameters. The process by which changes occur and the level of pharmacists' activities will also be assessed. The ultimate goal of the project is the development of an accompanying guide to facilitate the work of the pharmacist in monitoring complex patients in primary care medical clinics.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Health Services

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CIUSSS de la Capitale-Nationale

Québec, Quebec, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Willing to meet with the pharmacist and;
  • Consuming drugs of four or more different pharmacological classes or having to take at least four doses per day and;
  • aged 70 or over with at least two criteria of vulnerability or aged less than 70 with at least 3 criteria of vulnerability or had a recent loss of autonomy or in post- hospitalization with medication changes in the hospital.

Exclusion criteria

  • None

Treatment and study plan

Pharmacist clinical intervention

Other

Pharmacists will make a clinical intervention with patients. They will review patient drug therapy already prescribed in their usual care. This includes a medication reconciliation, an assessment of drug related problems, an assessment of the regimen complexity and adherence to treatment. A care plan will be elaborated. Moreover, immediate and future interventions with the patient or other health professionals will be implemented and monitored. There will be no drug or devices tested, it is a human clinical intervention by a pharmacist.

Primary outcomes

  1. Number of drug related problems

    Time frame: 3 to 6 months

Secondary outcomes

  1. Regimen complexity

    Time frame: 3 to 6 months

    Medication regimen complexity index (MRCI)

  2. Medication adherence

    Time frame: 3 to 6 months

    Proportion of days covered (PDC)

  3. Quality of care provided by the clinical team (pharmacists, doctors, nurses, etc.)

    Time frame: 3 to 6 months

    Quality indicators (proposed by INESSS)

Sponsors and collaborators

Lead sponsor

Laval University

Other

Collaborators

  • Fonds de la Recherche en Santé du Québec
  • McGill University
  • Université de Sherbrooke

Registry information

Acronym: FMG

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Nov 15, 2016
Registry last updated
Nov 15, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.